-
1
المؤلفون: Eva Domingo-Domenech, Sumana Devata, Kim Prier, Philippe Armand, Sylvia Schwarz, Amitkumar Mehta, Andres Forero-Torres, Craig B. Reeder, Andras Strassz, Antonia Rodriguez Izquierdo, Ramón García-Sanz, Taimur Sher, Robert T. Chen, Leila Alland, Cassandra Choe-Juliak, Stephen M. Ansell, Nancy L. Bartlett, Alex F. Herrera, Izidore S. Lossos
المصدر: Dipòsit Digital de la UB
Universidad de Barcelonaمصطلحات موضوعية: Oncology, Adult, Male, medicine.medical_specialty, CD30, Adolescent, Maximum Tolerated Dose, medicine.medical_treatment, Immunology, Population, Immunoteràpia, Dose-Response Relationship, Immunologic, Ki-1 Antigen, Pembrolizumab, Antibodies, Monoclonal, Humanized, Biochemistry, Proof of Concept Study, Transplantation, Autologous, Young Adult, Antigens, Neoplasm, Recurrence, Internal medicine, Antibodies, Bispecific, Antineoplastic Combined Chemotherapy Protocols, medicine, Refractory Hodgkin Lymphoma, Humans, education, Aged, education.field_of_study, business.industry, Receptors, IgG, Hematopoietic Stem Cell Transplantation, Cell Biology, Hematology, Immunotherapy, Middle Aged, Combined Modality Therapy, Hodgkin Disease, Immunity, Innate, Malaltia de Hodgkin, Transplantation, Tolerability, Pharmacodynamics, Female, Hodgkin's disease, business, Half-Life
وصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::992e4a32da4a80a7d2babe9fc223460a
https://pubmed.ncbi.nlm.nih.gov/33211835 -
2
المؤلفون: Andres Forero-Torres, Alex F. Herrera, Leila Alland, Cassandra Choe-Juliak, A. Rodriguez Izquierdo, Craig B. Reeder, Andras Strassz, Sumana Devata, Sylvia Schwarz, Kim Prier, P. Armand, Ramón García-Sanz, Eva Domingo-Domenech, S. M. Ansell, Amitkumar Mehta, Robert W. Chen, Izidore S. Lossos, Nancy L. Bartlett, Taimur Sher
المصدر: Hematological Oncology. 37:177-178
مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, Hematology, General Medicine, Pembrolizumab, Internal medicine, Relapsed refractory, medicine, Hodgkin lymphoma, In patient, Brentuximab vedotin, business, medicine.drug
-
3
المؤلفون: Ramón García-Sanz, Leila Alland, Eva Domingo-Domenech, Cassandra Choe-Juliak, Sumana Devata, Antonia Rodriguez Izquierdo, Sylvia Schwarz, Craig B. Reeder, Andras Strassz, Stephen M. Ansell, Robert W. Chen, Philippe Armand, Izidore S. Lossos, Taimur Sher, Kim Prier, Andres Forero-Torres, Nancy L. Bartlett
المصدر: Blood. 132:1620-1620
مصطلحات موضوعية: 0301 basic medicine, medicine.medical_specialty, Immunology, Population, Salvage therapy, Pembrolizumab, Neutropenia, Biochemistry, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Adverse effect, education, Brentuximab vedotin, health care economics and organizations, education.field_of_study, business.industry, Cell Biology, Hematology, medicine.disease, 030104 developmental biology, Tolerability, 030220 oncology & carcinogenesis, Cohort, business, medicine.drug
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::fc551501a976f91f4c809e5660ff7ad6
https://doi.org/10.1182/blood-2018-99-118506
